News Roche to file Actemra in inflamed artery disease Drug successful in late stage trial for giant cell arteritis
News Novartis drug gets fast US review in AML Midostaurin also under review in rare disease systemic mastocytosis
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
